logo
Twitter
Discord
Email
logo
Climb Bio, Inc.

Climb Bio, Inc.

NASDAQ•CLYM
CEO: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-08-10
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Contact Information
PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE, 19808-1609, United States
866-857-2596
eliemtx.com
Market Cap
$287.74M
P/E (TTM)
-5.6
38.2
Dividend Yield
--
52W High
$5.19
52W Low
$1.05
52W Range
77%
Rank49Top 66.7%
3.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.19+46.15%
4-Quarter Trend

FCF

-$12.25M+62.12%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Pipeline Advancement Milestones Met Budoprutug Phase 2 trial initiated across three indications. CLYM116 Phase 1 dosing expected by year-end 2025.
Nine-Month Net Loss Reduced Nine-month net loss narrowed substantially to $42.3M in 2025 from $65.5M in 2024, showing operational leverage.
Cash Runway Secured Through 2027 Cash, equivalents, and securities total $175.8M as of September 30, 2025. Sufficient funding projected through 2027.

Risk Factors

Continued Operating Losses Expected Anticipates substantial future losses; no product revenue source currently exists. Profitability remains highly uncertain.
Internal Control Material Weaknesses Material weaknesses in internal control over financial reporting remain unremediated as of September 30, 2025.
Reliance on Third-Party Suppliers Heavy reliance on third parties for manufacturing and clinical execution. Supply disruption risks development timelines.

Outlook

Budoprutug Clinical Data Expected Expect initial efficacy data from Budoprutug Phase 1b/2a trials in ITP and SLE in second half of 2026.
CLYM116 Phase 1 Completion Timeline Anticipate initial clinical data from CLYM116 Phase 1 trial in healthy volunteers in Australia by mid-2026.
Future Capital Requirements Anticipated Anticipates needing substantial financing in the future to fund operations beyond current cash runway projection.

Peer Comparison

Revenue (TTM)

Agenus Inc.AGEN
$106.83M
-33.4%
Seer, Inc.SEER
$16.33M
+14.5%
Ovid Therapeutics Inc.OVID
$6.61M
+946.6%

Gross Margin (Latest Quarter)

Vistagen Therapeutics, Inc.VTGN
100.0%
+0.0pp
Ovid Therapeutics Inc.OVID
87.1%
-12.9pp
Seer, Inc.SEER
51.2%
+3.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CLYM$287.74M-5.6-26.4%0.3%
CNTX$132.31M-5.2-30.9%0.2%
IKT$118.57M-3.2-57.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 24, 2026
|
EPS:-$0.19
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.19+46.2%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.13-92.8%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.31+404.9%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 25, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.53-17.7%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.13-13.3%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.81+852.6%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 15, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.06-92.7%
    N/A

  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 29, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.30+24.4%
    N/A